{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:41:48Z","timestamp":1793922108841,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105253","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:01:31Z","timestamp":1772848891000},"page":"105253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Bispecific antibodies in solid tumors: An Italian Association of Medical Oncology (AIOM) multidisciplinary perspective on immunology and vaccination"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9611-1164","authenticated-orcid":false,"given":"Angioletta","family":"Lasagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2026.105253_bib1","first-page":"1672","article-title":"Critically ill COVID-19 patients exhibit hyperactive cytokine responses associated with effector exhausted senescent T cells in acute infection","volume":"224","author":"Arcanjo","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105253_bib2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/curroncol32040198","article-title":"Pathogenesis, diagnosis, and management of cytokine release syndrome in patients with cancer: focus on infectious disease considerations","volume":"32","author":"Arvanitis","year":"2025","journal-title":"Curr. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105253_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/diseases12100231","article-title":"Cytokine storms and anaphylaxis following COVID-19 mRNA-LNP vaccination: mechanisms and therapeutic approaches","volume":"12","author":"Awaya","year":"2024","journal-title":"Diseases"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105253_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers17020282","article-title":"Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies","volume":"17","author":"Bangolo","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105253_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105253_bib7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105253_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105253_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581153","article-title":"Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform","volume":"16","author":"Grudzinska-Goebel","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105253_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473148","article-title":"Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances","volume":"45","author":"Guidi","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105253_bib11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105253_bib12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-025-01393-8","article-title":"Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed\/refractory multiple myeloma","volume":"15","author":"Jurgens","year":"2025","journal-title":"Blood Cancer J."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105253_bib14","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105253_bib15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105253_bib16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/OP-24-00935","article-title":"How should we manage the impact of antimicrobial resistance in patients with cancer? An oncological and infectious disease specialist point of view","volume":"21","author":"Lasagna","year":"2025","journal-title":"JCO Oncol. Pr."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105253_bib17","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.2217\/fon-2022-0277","article-title":"Infectious complications and immunotherapy: old pitfalls and new horizons","volume":"18","author":"Lasagna","year":"2022","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105253_bib18","first-page":"277.e1","article-title":"Pneumococcal conjugate vaccine does not induce humoral response when administrated within the six months after CD19 CAR T-cell therapy","volume":"29","author":"Lee","year":"2023","journal-title":"Transpl. Cell Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105253_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.critrevonc.2026.105253_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010331","article-title":"Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy","volume":"13","author":"Middelburg","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105253_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105253_bib23","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40780-025-00506-6","article-title":"A case of hepatitis B virus reactivation after elranatamab therapy in a patient with multiple myeloma","volume":"11","author":"Nishimura","year":"2025","journal-title":"J. Pharm. Health Care Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105253_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101215","article-title":"Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)","volume":"8","author":"Pedrazzoli","year":"2023","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105253_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100548","article-title":"Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)","volume":"7","author":"Pedrazzoli","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105253_bib27","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105253_bib29","first-page":"3168","article-title":"Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies","volume":"110","author":"Rees","year":"2025","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105253_bib30","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40121-017-0146-1","article-title":"Infections in cancer patients with solid tumors: a review","volume":"6","author":"Rolston","year":"2017","journal-title":"Infect. Dis. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105253_bib32","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2026.105253_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.824511","article-title":"Neurological manifestations related to immune checkpoint inhibitors: reverse translational research by using the European real-world safety data","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/v17010133","article-title":"Herpesvirus infections after chimeric antigen receptor T-cell therapy and bispecific antibodies: a review","volume":"17","author":"Sassine","year":"2025","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105253_bib35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105253_bib36","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2024015406","article-title":"Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders","volume":"9","author":"Serna","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12985-024-02375-1","article-title":"Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis","volume":"21","author":"Sharifi Aliabadi","year":"2024","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105253_bib39","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"2 Pt A","key":"10.1016\/j.critrevonc.2026.105253_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105253_bib41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clml.2023.03.002","article-title":"Response to COVID-19 vaccination post-CAR T therapy in patients with non-hodgkin lymphoma and multiple myeloma","volume":"23","author":"Wiedmeier-Nutor","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105253_bib42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105253_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:47:36Z","timestamp":1775908056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["S104084282600140X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105253","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies in solid tumors: An Italian Association of Medical Oncology (AIOM) multidisciplinary perspective on immunology and vaccination","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105253"}}